Cwm LLC Decreases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Cwm LLC reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 20.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,214 shares of the medical research company’s stock after selling 5,302 shares during the period. Cwm LLC’s holdings in Edwards Lifesciences were worth $1,334,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the company. Nomura Holdings Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $933,000. GAMMA Investing LLC lifted its position in Edwards Lifesciences by 12.7% during the first quarter. GAMMA Investing LLC now owns 2,587 shares of the medical research company’s stock valued at $247,000 after purchasing an additional 292 shares in the last quarter. Rise Advisors LLC grew its holdings in Edwards Lifesciences by 125.0% during the first quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 265 shares during the period. Welch Group LLC purchased a new stake in Edwards Lifesciences in the first quarter worth about $234,000. Finally, Perpetual Ltd bought a new position in shares of Edwards Lifesciences in the first quarter worth about $236,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. TD Cowen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price objective for the company from $100.00 to $70.00 in a research note on Thursday, July 25th. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Bank of America cut shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and lowered their target price for the company from $105.00 to $75.00 in a research note on Thursday, July 25th. Citigroup cut their price target on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research note on Tuesday, October 1st. Finally, Royal Bank of Canada lowered their price objective on Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Fifteen research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $75.81.

Edwards Lifesciences Price Performance

EW stock opened at $68.30 on Thursday. The stock has a market cap of $41.16 billion, a PE ratio of 29.44, a P/E/G ratio of 2.83 and a beta of 1.13. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a 50-day moving average price of $67.59 and a 200 day moving average price of $79.52. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.66 earnings per share. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock worth $1,099,238 in the last quarter. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.